Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoligratinib + fulvestrant
- Development stage
- Phase 2
- Lead developer
- Debiopharm
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A combination therapy consisting of zoligratinib (DEBIO 1347), an oral selective FGFR1-3 inhibitor, and fulvestrant, a selective estrogen receptor downregulator (SERD). This combination is being investigated for the treatment of estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer with FGFR gene amplifications. The combination aims to target both the estrogen receptor pathway and the FGFR signaling pathway, which may be involved in endocrine resistance mechanisms.
02
Targets
ESR1 (ERα)ESR2 (ERβ)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on zoligratinib + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoligratinib + fulvestrant.